PL355102A1 - Receptor APRIL (BCMA) oraz jego zastosowania - Google Patents

Receptor APRIL (BCMA) oraz jego zastosowania

Info

Publication number
PL355102A1
PL355102A1 PL00355102A PL35510200A PL355102A1 PL 355102 A1 PL355102 A1 PL 355102A1 PL 00355102 A PL00355102 A PL 00355102A PL 35510200 A PL35510200 A PL 35510200A PL 355102 A1 PL355102 A1 PL 355102A1
Authority
PL
Poland
Prior art keywords
bcma
april receptor
april
receptor
antibodies
Prior art date
Application number
PL00355102A
Other languages
English (en)
Other versions
PL204010B1 (pl
Inventor
Pascal Schneider
Jeffrey Thompson
Teresa Cachero
Christine Ambrose
Paul Rennert
Original Assignee
Biogen, Inc.
Apotech R & D, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27388102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL355102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Inc., Apotech R & D, S.A. filed Critical Biogen, Inc.
Publication of PL355102A1 publication Critical patent/PL355102A1/pl
Publication of PL204010B1 publication Critical patent/PL204010B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
PL355102A 1999-10-06 2000-10-05 Zastosowanie polipeptydu zdolnego do wiązania liganda indukcyjnego proliferację (APRIL) PL204010B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15793399P 1999-10-06 1999-10-06
US18180700P 2000-02-11 2000-02-11
US21568800P 2000-06-30 2000-06-30

Publications (2)

Publication Number Publication Date
PL355102A1 true PL355102A1 (pl) 2004-04-05
PL204010B1 PL204010B1 (pl) 2009-12-31

Family

ID=27388102

Family Applications (1)

Application Number Title Priority Date Filing Date
PL355102A PL204010B1 (pl) 1999-10-06 2000-10-05 Zastosowanie polipeptydu zdolnego do wiązania liganda indukcyjnego proliferację (APRIL)

Country Status (30)

Country Link
US (1) US7276241B2 (pl)
EP (3) EP1847273A1 (pl)
JP (2) JP4880155B2 (pl)
KR (1) KR100759295B1 (pl)
CN (1) CN1263507C (pl)
AT (1) ATE360434T1 (pl)
AU (1) AU776852B2 (pl)
BG (1) BG65473B1 (pl)
BR (1) BR0014583A (pl)
CA (1) CA2386463C (pl)
CZ (1) CZ297633B6 (pl)
DE (1) DE60034586T2 (pl)
DK (1) DK1223964T3 (pl)
EA (1) EA005601B1 (pl)
EE (1) EE05212B1 (pl)
GE (1) GEP20043375B (pl)
HK (1) HK1044710B (pl)
HU (1) HUP0203567A2 (pl)
IL (3) IL148839A0 (pl)
IS (1) IS6322A (pl)
MX (1) MXPA02003393A (pl)
NO (1) NO331683B1 (pl)
NZ (1) NZ517907A (pl)
PL (1) PL204010B1 (pl)
RS (1) RS51602B (pl)
SK (1) SK286331B6 (pl)
TR (1) TR200200912T2 (pl)
UA (1) UA74798C2 (pl)
WO (1) WO2001024811A1 (pl)
ZA (1) ZA200202578B (pl)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
DK1210425T4 (en) 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
DK1255558T3 (da) * 2000-02-16 2006-10-23 Genentech Inc Anti-april antistoffer og hybridomaceller
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
SI1436003T1 (sl) 2001-05-24 2010-02-26 Zymogenetics Inc TACI-imunoglobulinski fuzijski proteini
CA2446734A1 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
WO2003014294A2 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002333502A1 (en) * 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
AU2003221256A1 (en) * 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
CA2492447A1 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
KR20060027801A (ko) * 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
MXPA06004301A (es) 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
ES2443996T3 (es) 2004-04-22 2014-02-21 Agensys, Inc. Anticuerpos y moléculas derivadas de los mismos que se unen a proteínas STEAP-1
CN1786016B (zh) * 2004-12-09 2010-12-29 中国人民解放军军事医学科学院基础医学研究所 一种人工构建的生物活性分子及其制备方法
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
AU2006209237B2 (en) * 2005-01-28 2010-06-24 Biogen Ma Inc. Use of BAFF to treat Th2-mediated conditions
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
SI2502938T1 (sl) 2006-10-27 2015-05-29 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
EP2488200A4 (en) * 2009-10-14 2013-06-12 Merck Sharp & Dohme APRIL ANTAGONISTS AND METHOD FOR THEIR USE
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
ES2731232T3 (es) 2013-03-15 2019-11-14 Inst Nat Sante Rech Med Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
JP6484237B2 (ja) 2013-11-19 2019-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化増殖誘導リガンド遺伝子を有する非ヒト動物
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
PE20180795A1 (es) 2015-08-17 2018-05-09 Janssen Pharmaceutica Nv Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
KR20190008171A (ko) * 2015-11-13 2019-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-bcma 폴리펩티드 및 단백질
MA43308A (fr) 2015-11-25 2018-10-03 Visterra Inc Molécules d'anticorps se liant à april et leurs utilisations
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
AU2017281034B2 (en) 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
WO2018052503A1 (en) 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
BR112019008426A2 (pt) 2016-11-02 2019-09-03 Engmab Sarl anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
BR112019018767A2 (pt) 2017-04-03 2020-05-05 Hoffmann La Roche anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
WO2018237037A2 (en) 2017-06-20 2018-12-27 Teneobio, Inc. HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
AU2018288803A1 (en) 2017-06-20 2020-02-06 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
JP2022537931A (ja) 2019-06-14 2022-08-31 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
KR20220068984A (ko) 2019-07-30 2022-05-26 상하이 한서 바이오메디컬 컴퍼니 리미티드 항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
TW202330622A (zh) 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
CA3182697A1 (en) 2020-05-11 2021-11-18 Janssen Biotech, Inc. Methods for treating multiple myeloma
MX2022014995A (es) * 2020-05-29 2023-02-09 Chinook Therapeutics Inc Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
WO2022006316A1 (en) 2020-06-30 2022-01-06 Teneobio, Inc. Multi-specific antibodies binding to bcma
CR20230398A (es) 2021-02-16 2023-11-15 Janssen Pharmaceutica Nv Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
DK0897390T3 (da) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumornekrosefaktor-delta og -epsilon
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
WO1998055621A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EA005411B1 (ru) * 1997-09-12 2005-02-24 Апотек Р Энд Д Са Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
TR200101998T2 (tr) * 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
PL198934B1 (pl) 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
EP1157126A4 (en) * 1999-02-24 2005-03-02 Gen Hospital Corp PROCESS FOR CLONING INTERMEDIATE PRODUCTS FOR SIGNAL TRANSDUCTION
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
DK1210425T4 (en) * 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
CA2399387C (en) 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
DK1255558T3 (da) * 2000-02-16 2006-10-23 Genentech Inc Anti-april antistoffer og hybridomaceller
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
CA2419661A1 (en) 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1456347A4 (en) 2001-11-16 2006-08-02 Human Genome Sciences Inc ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE

Also Published As

Publication number Publication date
JP2003510366A (ja) 2003-03-18
US7276241B2 (en) 2007-10-02
GEP20043375B (en) 2004-11-25
BG106670A (en) 2002-12-29
EP1223964A1 (en) 2002-07-24
YU25302A (sh) 2005-06-10
ZA200202578B (en) 2003-07-02
TR200200912T2 (tr) 2002-07-22
JP4880155B2 (ja) 2012-02-22
EP2324844A3 (en) 2013-12-11
NZ517907A (en) 2004-01-30
EA005601B1 (ru) 2005-04-28
NO20021594D0 (no) 2002-04-04
DE60034586T2 (de) 2008-02-28
WO2001024811A1 (en) 2001-04-12
AU776852B2 (en) 2004-09-23
CN1263507C (zh) 2006-07-12
KR20020053066A (ko) 2002-07-04
IL148839A (en) 2015-01-29
DE60034586D1 (de) 2007-06-06
CZ297633B6 (cs) 2007-02-14
EP1223964B1 (en) 2007-04-25
AU7864500A (en) 2001-05-10
ATE360434T1 (de) 2007-05-15
SK4512002A3 (en) 2002-12-03
SK286331B6 (en) 2008-07-07
BG65473B1 (bg) 2008-09-30
EE200200181A (et) 2003-06-16
US20030082175A1 (en) 2003-05-01
UA74798C2 (uk) 2006-02-15
CN1399556A (zh) 2003-02-26
CA2386463A1 (en) 2001-04-12
HK1044710B (zh) 2007-12-07
MXPA02003393A (es) 2004-08-19
IL204401A (en) 2014-12-31
CZ20021169A3 (cs) 2002-09-11
NO20021594L (no) 2002-06-05
PL204010B1 (pl) 2009-12-31
KR100759295B1 (ko) 2007-09-18
NO331683B1 (no) 2012-02-20
BR0014583A (pt) 2002-06-11
RS51602B (sr) 2011-08-31
EP1847273A1 (en) 2007-10-24
IL148839A0 (en) 2002-09-12
CA2386463C (en) 2012-02-07
EP2324844A2 (en) 2011-05-25
HUP0203567A2 (hu) 2003-02-28
EA200200427A1 (ru) 2002-12-26
DK1223964T3 (da) 2007-08-27
JP2011079863A (ja) 2011-04-21
EE05212B1 (et) 2009-10-15
IS6322A (is) 2002-03-22
HK1044710A1 (en) 2002-11-01

Similar Documents

Publication Publication Date Title
HK1044710A1 (en) April receptor (bcma) and uses thereof
SK500172015A3 (pl)
IL144578A0 (en) Antibodies specific to kdr and uses thereof
EP1053351A4 (en) NOVEL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMIL MOLECULES AND USES THEREOF
WO2001083550A3 (en) Gpr22 modulators as appetite-control agents
AU6603098A (en) Device to facilitate the placing of slurries in up-holes
AUPO566897A0 (en) Device to facilitate the placing of slurries in up holes